Improvements in Liver Fibroinflammation (as Assessed by Corrected T1 [cT1]) with HTD1801 (Berberine Ursodeoxycholate) Treatment in Patients with Nonalcoholic Steatohepatitis and Type 2 Diabetes Mellitus